SCOPUS 정보 검색 플랫폼

Annals of Pharmacotherapy

Volumn 36, Issue 5, 2002, Pages 933-935

Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a

(2) Lamb, Matthew W a Martin, Nancy E a

a HOFFMANN LA ROCHE INC (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A;

ANTIVIRAL ACTIVITY; BODY WEIGHT; DISTRIBUTION VOLUME; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; STEADY STATE; VIRUS LOAD;

ANTIVIRAL AGENTS; BODY WEIGHT; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; METABOLIC CLEARANCE RATE; OBESITY; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 0036093457 PISSN: 10600280 EISSN: None Source Type: Journal
DOI: 10.1177/106002800203600501 Document Type: Article

Times cited : (32)

References (19)

1
- 0017246221
- Pathophysiological and disease-induced changes in drug distribution volume: Pharmacokinetic implications
- (1976) Clin Pharmacokinet , vol.1 , pp. 204-218
- Klotz, U.¹

2
- 0030737521
- Antimicrobial dosing in obese patients
- (1997) Clin Infect Dis , vol.25 , pp. 112-118
- Wurtz, R.¹ Itokazu, G.² Rodvold, K.³

3
- 0344598789
- Individualization: Age and weight
- Rowland M, Tozer T, eds. Philadelphia: Williams & Wilkins
- (1995) Clinical pharmacokinetics concepts and applications. 3rd ed. , pp. 230-248
- Rowland, M.¹ Tozer, T.²

4
- 0035811625
- Hepatitis C virus infection
- (2001) N Engl J Med , vol.345 , pp. 41-52
- Lauer, G.M.¹ Walker, B.D.²

5
- 0021196014
- Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection
- (1984) Clin Pharmacol Ther , vol.35 , pp. 722-727
- Wills, R.J.¹ Dennis, S.² Speigel, H.E.³ Gibson, D.M.⁴ Nadler, P.I.⁵

6
- 0006035962
- Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-interferon) and interferon α-2a to healthy subjects
- Dallas, TX, November 4-6
- (1998) 49th Annual Meeting of the American Association for the Study of Liver Disease
- Xu, Z.-X.¹ Hoffman, J.² Patel, I.³ Joubert, P.⁴

7
- 4243791372
- Branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)
- Dallas, TX, November 5-9
- (1999) 50th Annual Meeting of the American Association for the Study of Liver Disease
- Algranati, N.E.¹ Sy, S.² Modi, M.W.³

8
- 17744389383
- Efficacy and Safety of pegylated (40kDa) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C
- (2001) Hepatology , vol.33 , pp. 433-438
- Reddy, K.R.¹ Wright, T.L.² Pockros, P.J.³ Shiffman, M.⁴ Everson, G.⁵ Reindollar, R.⁶

9
- 0006036258
- Nutley, NJ: Hoffmann-La Roche, Inc
- (2001) Data on file. Peginterferon alfa-2a

10
- 0034979529
- Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C
- (2001) Clin Pharmacol Ther , vol.69 , pp. 407-421
- Jen, J.F.¹ Glue, P.² Ezzet, F.³ Chung, C.⁴ Gupta, S.K.⁵ Jacobs, S.⁶

11
- 0034619946
- Peginterferon α-2a in patients with chronic hepatitis C
- (2000) N Engl J Med , vol.343 , pp. 1666-1672
- Zeuzem, S.¹ Feinman, S.V.² Rasenack, J.³ Heathcote, E.J.⁴ Lai, M.-Y.⁵ Gane, E.⁶

12
- 0034619980
- Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
- (2000) N Engl J Med , vol.343 , pp. 1673-1680
- Heathcote, E.J.¹ Shiffman, M.L.² Cooksley, G.E.³ Dusheiko, G.M.⁴ Lee, S.S.⁵ Balart, L.⁶

13
- 0028959527
- Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2a given by subcutaneous injection in healthy male volunteers
- (1995) J Clin Pharmacol , vol.35 , pp. 281-284
- Zhi, J.¹ Teller, S.B.² Satoh, H.³ Koss-Twardy, S.G.⁴ Luke, D.R.⁵

14
- 0006133474
- Prognostic factors and early predictability of sustained viral response (SVR) in patients treated with pegylated (40kDa) interferon alfa-2a (Pegasys): A new profile
- Dallas, TX, October 27-31
- (2000) 51st Annual Meeting of the American Association for the Study of Liver Disease
- Lee, S.S.¹ Heathcote, E.J.² Reddy, K.R.³ Zeuzem, S.⁴ Fried, M.W.⁵ Wright, T.L.⁶

15
- 0030885469
- Factors predictive of a beneficial response to therapy of hepatitis C
- (1997) Hepatology , vol.26 , pp. 122S-127S
- Davis, G.L.¹ Lau, J.Y.N.²

16
- 0033965331
- Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
- The ALGOVIRC Project Group
- (2000) Hepatology , vol.31 , pp. 211-218
- Poynard, T.¹ McHutchison, J.² Goodman, Z.³ Ling, M.H.⁴ Albrecht, J.K.⁵

17
- 0031025974
- Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C
- (1997) Dig Dis Sci , vol.42 , pp. 178-185
- Lam, N.P.¹ Pitrak, D.² Speralakis, R.³ Lau, A.H.⁴ Wiley, T.E.⁵ Layde, T.J.⁶

18
- 0006071820
- Steatosis on liver biopsy in patients with hepatitis C is associated with obesity and diabetes, but not with lifetime alcohol use
- Dallas, TX, October 27-31
- (2000) 51st Annual Meeting of the American Association for the Study of Liver Disease
- Monto, A.¹ Alonzo, J.² Hirsch, K.³ Watson, J.⁴ Bass, N.⁵ Wright, T.L.⁶

19
- 0006035963
- Weight reduction in patients with chronic hepatitis C improves liver histology and biochemistry
- Dallas, TX, October 27-31
- (2000) 51st Annual Meeting of the American Association for the Study of Liver Disease
- Clouston, A.D.¹ Jonsson, J.R.² Hickman, I.³ Shorthouse, C.⁴ Mori, T.⁵ Prins, J.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.